Drugs / [68Ga]ABY-025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01858116 | Apr 2013 → Jun 2014 | breast cancer | Biomedical Radiation Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-30 | Affibody | Results First ten HER2-low patients dosed in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025 affibody.se ↗
Preliminary results from the first ten patients indicate 68Ga-ABY-025 uptake in cancer lesions in all patients with HER2-low metastatic breast cancer. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-30 | Affibody | First ten HER2-low patients dosed in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025 affibody.se ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]ABY-025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01858116 ↗ |
| Modality | Peptide | “ABY-025 peptide” NCT01858116 ↗ |
| Route | Intravenous | “Intravenous injection followed by PET imaging” NCT01858116 ↗ |